Webdisclosure.com

Search

CENTOGENE AG CENTOGENE Welcomes Germany's Chancellor Dr. Angela Merkel

Directive transparence : information réglementée

23/05/2019 17:00

DGAP-News: CENTOGENE AG / Key word(s): Miscellaneous
CENTOGENE Welcomes Germany's Chancellor Dr. Angela Merkel

23.05.2019 / 17:00
The issuer is solely responsible for the content of this announcement.


CENTOGENE Welcomes Germany's Chancellor Dr. Angela Merkel

Cambridge, MA USA & Rostock, Germany 23 May, 2019 - CENTOGENE today welcomed Germany's Chancellor Dr. Angela Merkel to its headquarters together with Manuela Schwesig, Minister-President of Mecklenburg-Vorpommern. The visit focused on explaining CENTOGENE's capabilities in the field of genetics, and in particular demonstrating the Company's advancing artificial intelligence program.

Dr. Arndt Rolfs, CEO CENTOGENE commented: "We are extremely honored to have welcomed Dr. Angela Merkel and Manuela Schwesig to CENTOGNE. In Germany today and in particular across Mecklenburg-Vorpommern, there is a strategic agenda that prioritizes the digitization of the economy. Today we demonstrated to our esteemed guests CENTOGENE's work in rare genetic diseases and our digital strategy with leading-edge artificial intelligence programs."

"Artificial intelligence is enabling the integration of patient-focused metabolomics, proteomics, genetic data in our diagnostic business, while for our pharmaceutical solutions AI is enabling the rapid discovery of biomarkers, cohort identification, and other patterns in our genomic, proteomic and phenotype datasets. Ultimately however, all our work at CENTOGENE is underpinned with a priority on bringing hope to patients and their families by shortening the diagnostic odyssey."

- end -

About CENTOGENE

CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. We are focused on bringing rationality to treatment decisions and accelerating the development of new orphan drugs by using our knowledge of the global rare disease market, including our epidemiological and clinical heterogeneity, and our innovative biomarkers.

As one of the largest rare disease companies worldwide, CENTOGENE is dedicated to transforming the science of genetic information into solutions and creating hope for patients with rare diseases and their families. www.centogene.com

###

CENTOGENE
Ross Bethell
Director, Corporate Communications
ross.bethell@centogene.com



23.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


815319  23.05.2019 

fncls.ssp?fn=show_t_gif&application_id=815319&application_name=news&site_id=symex